Kadar hs-CRP pada pasien DM tipe 2 Dengan dan Tanpa Hipertensi
DAFTAR PUSTAKA
1. Pepys MB, Hirschfield GM. C-Reactive Protein:A Critical Update. The
Journal Of Clinical Investigation, 2003, Vol.111, p. 1805-1811.
2. Agrawal A, Hammond DJ, and Singh SK,Atherosclerosis-related functions
of C-reactive protein Cardiovasc Hematol Disord Drug Targets. 2010
December 1; 10(4): 235–240.
3. Cushman
RM,
Cardiovascular
Emerging
Disease
Biomarkers
and
for
Primary
Stroke,Inflammation
Prevention
Biomarkers
of
and
Cardiovascular Disease,2009, chapter 3, p;11-15
4. Ridker PM, Hennekens CH,. Buring JE, And Rifai N; C-Reactive Protein
And Other Markers Of Inflammation In The Prediction Of Cardiovascular
Disease In Women; Engl J Med 2000; 342:836.
5. Janghorbani M,Isfahan MA,Hypertension in type 2 diabetes mellitus in
Isfahan, Diabetes Research and Clinical Practice, N. Eng J Med. 2005;
352; 1685-95.
6. Paffen E, Moniek P.M, C-reactive protein in atherosclerosis: A causal
factor? Cardiovascular Research 2006; 71; 30 – 39
7. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-Reactive Protein and
Other
Markers of Inflammation in the Prediction of Cardiovascular
Disease in Women, N Engl J Med 2000; 342:836-843
8. Nilsson PM, Gudbjo¨rnsdottir S, Eliasson B, Cederholm J, Hypertension in
diabetes: trends in clinical control in repeated large-scale national surveys
from Sweden, Journal of Human Hypertension 2003; 17; 37–44.
9. Epstein M, Sower JR. Diabetes and Hypertension, Journal of The
American Heart Association. 1992; 19;403-18.
10. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M, Endothelial
Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Medicinal Chemistry, 2009, 16;94-112
11. Lima LM, Carvalho M, Soares AL, Sabino AP, Fernandes AP,HighSensitivity C-Reactive Protein In Subjects With Type 2 Diabetes Mellitus
And/Or High Blood Pressure. Arq Bras EndocrinolMetab 2007;51/6:956960
53
12. Anand AV, Muneeb M, Divya N, Senthil R, Kapoor MMA, et.al. Clinical
Significance Of Hypertension, Diabetes And Inflammation, As Predictor Of
Cardiovascular Disease. Int J Biol Med Res. 2011; 2(1): 369-373.
13. Taylor Aa, Pathophysiology Of Hypertension And Endothelial Dysfunction
In Patients With Diabetes Mellitus. Endocrinol Metab Clin North Am. 2001
Dec;30(4):983-97
14. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, et al, Association
Of Systolic Blood Pressure With Macrovascular And Microvascular
Complications Of Type 2 Diabetes (Ukpds 36): Prospective Observational
Study, BMJ. 2000;321:412-9.
15. Permana H,. Pengelolaan Hipertensi Pada Diabetes Mellitus Tipe 2. Fk
Unpad, Bandung, 2008.
16. Khera
A.
Biomarkers
In
Heart
Diseases,
Blackwell
Publishing..
Massachussetts,1st Edition,2008, p:161-180.
17. Bratawidjaja Kg. Imunologi Dasar. Gaya Baru, Jakarta, ,2006, Ed:7; Hal.
13-15, 391-408.
18. Hegde
V,
Ching
I,
Vascular
Inflammation:
A
New
Horizon
in
Cardiovascular RiskAssessment. In: Gasparyan AY (Ed.). Cardiovascular
Risk Factors, 2012, Chapter 5,P. 103-140.
19. Libby P, Ridker PM, GK. Hansson, Inflammation In Atherosclerosis From
Pathophysiology,Journal Of The American College Of Cardiology, 2009,
Vol. 54, No. 23.
20. Handojo I. Imunoasai Terapan Pada Beberapa Penyakit Infeksi. Airlangga
University Press. Cetakan I. Surabaya, 2004, Hal. 272-285
21. Roche Diagnostic GmbH. CRPHS. Roche diagnostics. Indianapolis. 2011;
p.1-4.
22. International Diabetes Federation. IDF Clinical Guidelines Task Force.
Globa Guideline For Type 2 Diabetes. Brussels, 2005
23. Green FS, Baxter JD, Endokinologi Dasar Dan Klinik,Edisi 4, 2000; Hal
742.
24. Perkumpulan Endokrinologi Indonesia. Konsensus Pengelolaan Dan
Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2006. Pb Perkeni,
Jakarta 2006 : 1 – 47.
25. Groop Lc. Type 2 Diabetes Mellitus: Pathogenesis And Treatment. In
Endocrinology And Metabolism. Mc Graw-Hill, England. 2001: p 607- 14.
54
26. American
Diabetes
Association;
Diagnosis
and
Classification
of
DiabetesMellitus, Diabetes Care. 2010 Jan; 33(Suppl 1): S62–S69.
27. Lancet, Principles Of Phatogenesis And Therapy. 2005 ; 365: 1333- 34.
28. Bakker Sj, Gans R, Maaten Jc, The Potential Role Of Adeosine In
Pathophysiology Of The Insulin Resistance Syndroma. Atherosklerosis
2001: 155: 283-90.
29. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology,
Diagnosis And Prognostic Implications Of Endothelial Dysfunction. Ann
Med. 2008;40(3):180-96.
30. Hanson Gk ,Inflammation, Atherosclerosis, And Artery Coronary Disease.
N. Eng J Med. 2005; 352; 1685-95).
31. Yang
H,
Jin X,
Lam CW,
Yan
SK,Oxidative
stress
and
diabetesmellitus; Clinical Chemistry and Laboratory Medicine , 2011,
Volume 49, Issue 11 Pages 1773–1782
32. Moser M, World Health Organization-International Society of Hypertension
Guidelines for the Management of Hypertension, J Clin Hypertens
(Greenwich). 1999 Jul;1(1):48-54
33. Yogiantoro, M. Hipertensi Esensial.; Buku Ajar Penyakit Ilmu Penyakit
Dalam. Pusat Penerbitan Ilmu Penyakit Dalam FK UI. Jakarta : Ed 4
34. Beevers G, Lip GYH, O'brien E; The Pathophysiology Of Hypertension ,
Bmj, 2001, Volume 322.
35. Gilbert RE, Jasik M, DeLuise M, O'Callaghan CJ, Cooper ME. Diabetes
and hypertension. In: Australian Diabetes Society position statement.
Medical Journal of Australian 1995; 163: 372-375.
36. Standley PR, Bakir MH, Sowers JR. Vascular insulin abnormalities,
hypertension, and accelerated atherosclerosis: Am J Kidney Dis. 1993
Jun;21(6 Suppl 3):39-46
37. Inoguchi T, Li P, Umeda F. High Glucose Level And Free Fatty Acid
Stimulate Reactive Oxygen Species Production Through Protein Kinase CDependent Activation Of Nad(P)H Oxidase In Cultured Vascular Cells.
Diabetes. 2000;49:1939-1945.
38. Ridwan M, Gotera W, Pengaruh Insulin Terhadap Fungsi Kardiovaskular; J
Peny Dalam, 2009, Volume 10, Nomor 2, p;151-152
55
39. Sowers Jr, Sowers Ps, Peuler Jd. Role Of Insulin Resistance And
Hyperinsulinemia In Development Of Hypertension And Atherosclerosis. J
Lab Clin Metab. 1994;123:647-652.
40. KimJ, MontagnaniM, KohKK,QuonMJ: Reciprocal Relationships Between
Insulin
Resistance
and
Endothelial
Dysfunction
Molecular
and
Pathophysiological Mechanisms ; Circulation. 2006;113:1888-1904.
41. Ramasamy R, Yan SF, Schmidt AM, Receptor for AGE (RAGE): signaling
mechanisms in the pathogenesis of diabetes and its complications, Annals
of the New York Academy of Sciences. 2011 Dec;43:88-102.
56
1. Pepys MB, Hirschfield GM. C-Reactive Protein:A Critical Update. The
Journal Of Clinical Investigation, 2003, Vol.111, p. 1805-1811.
2. Agrawal A, Hammond DJ, and Singh SK,Atherosclerosis-related functions
of C-reactive protein Cardiovasc Hematol Disord Drug Targets. 2010
December 1; 10(4): 235–240.
3. Cushman
RM,
Cardiovascular
Emerging
Disease
Biomarkers
and
for
Primary
Stroke,Inflammation
Prevention
Biomarkers
of
and
Cardiovascular Disease,2009, chapter 3, p;11-15
4. Ridker PM, Hennekens CH,. Buring JE, And Rifai N; C-Reactive Protein
And Other Markers Of Inflammation In The Prediction Of Cardiovascular
Disease In Women; Engl J Med 2000; 342:836.
5. Janghorbani M,Isfahan MA,Hypertension in type 2 diabetes mellitus in
Isfahan, Diabetes Research and Clinical Practice, N. Eng J Med. 2005;
352; 1685-95.
6. Paffen E, Moniek P.M, C-reactive protein in atherosclerosis: A causal
factor? Cardiovascular Research 2006; 71; 30 – 39
7. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-Reactive Protein and
Other
Markers of Inflammation in the Prediction of Cardiovascular
Disease in Women, N Engl J Med 2000; 342:836-843
8. Nilsson PM, Gudbjo¨rnsdottir S, Eliasson B, Cederholm J, Hypertension in
diabetes: trends in clinical control in repeated large-scale national surveys
from Sweden, Journal of Human Hypertension 2003; 17; 37–44.
9. Epstein M, Sower JR. Diabetes and Hypertension, Journal of The
American Heart Association. 1992; 19;403-18.
10. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M, Endothelial
Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Medicinal Chemistry, 2009, 16;94-112
11. Lima LM, Carvalho M, Soares AL, Sabino AP, Fernandes AP,HighSensitivity C-Reactive Protein In Subjects With Type 2 Diabetes Mellitus
And/Or High Blood Pressure. Arq Bras EndocrinolMetab 2007;51/6:956960
53
12. Anand AV, Muneeb M, Divya N, Senthil R, Kapoor MMA, et.al. Clinical
Significance Of Hypertension, Diabetes And Inflammation, As Predictor Of
Cardiovascular Disease. Int J Biol Med Res. 2011; 2(1): 369-373.
13. Taylor Aa, Pathophysiology Of Hypertension And Endothelial Dysfunction
In Patients With Diabetes Mellitus. Endocrinol Metab Clin North Am. 2001
Dec;30(4):983-97
14. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, et al, Association
Of Systolic Blood Pressure With Macrovascular And Microvascular
Complications Of Type 2 Diabetes (Ukpds 36): Prospective Observational
Study, BMJ. 2000;321:412-9.
15. Permana H,. Pengelolaan Hipertensi Pada Diabetes Mellitus Tipe 2. Fk
Unpad, Bandung, 2008.
16. Khera
A.
Biomarkers
In
Heart
Diseases,
Blackwell
Publishing..
Massachussetts,1st Edition,2008, p:161-180.
17. Bratawidjaja Kg. Imunologi Dasar. Gaya Baru, Jakarta, ,2006, Ed:7; Hal.
13-15, 391-408.
18. Hegde
V,
Ching
I,
Vascular
Inflammation:
A
New
Horizon
in
Cardiovascular RiskAssessment. In: Gasparyan AY (Ed.). Cardiovascular
Risk Factors, 2012, Chapter 5,P. 103-140.
19. Libby P, Ridker PM, GK. Hansson, Inflammation In Atherosclerosis From
Pathophysiology,Journal Of The American College Of Cardiology, 2009,
Vol. 54, No. 23.
20. Handojo I. Imunoasai Terapan Pada Beberapa Penyakit Infeksi. Airlangga
University Press. Cetakan I. Surabaya, 2004, Hal. 272-285
21. Roche Diagnostic GmbH. CRPHS. Roche diagnostics. Indianapolis. 2011;
p.1-4.
22. International Diabetes Federation. IDF Clinical Guidelines Task Force.
Globa Guideline For Type 2 Diabetes. Brussels, 2005
23. Green FS, Baxter JD, Endokinologi Dasar Dan Klinik,Edisi 4, 2000; Hal
742.
24. Perkumpulan Endokrinologi Indonesia. Konsensus Pengelolaan Dan
Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2006. Pb Perkeni,
Jakarta 2006 : 1 – 47.
25. Groop Lc. Type 2 Diabetes Mellitus: Pathogenesis And Treatment. In
Endocrinology And Metabolism. Mc Graw-Hill, England. 2001: p 607- 14.
54
26. American
Diabetes
Association;
Diagnosis
and
Classification
of
DiabetesMellitus, Diabetes Care. 2010 Jan; 33(Suppl 1): S62–S69.
27. Lancet, Principles Of Phatogenesis And Therapy. 2005 ; 365: 1333- 34.
28. Bakker Sj, Gans R, Maaten Jc, The Potential Role Of Adeosine In
Pathophysiology Of The Insulin Resistance Syndroma. Atherosklerosis
2001: 155: 283-90.
29. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology,
Diagnosis And Prognostic Implications Of Endothelial Dysfunction. Ann
Med. 2008;40(3):180-96.
30. Hanson Gk ,Inflammation, Atherosclerosis, And Artery Coronary Disease.
N. Eng J Med. 2005; 352; 1685-95).
31. Yang
H,
Jin X,
Lam CW,
Yan
SK,Oxidative
stress
and
diabetesmellitus; Clinical Chemistry and Laboratory Medicine , 2011,
Volume 49, Issue 11 Pages 1773–1782
32. Moser M, World Health Organization-International Society of Hypertension
Guidelines for the Management of Hypertension, J Clin Hypertens
(Greenwich). 1999 Jul;1(1):48-54
33. Yogiantoro, M. Hipertensi Esensial.; Buku Ajar Penyakit Ilmu Penyakit
Dalam. Pusat Penerbitan Ilmu Penyakit Dalam FK UI. Jakarta : Ed 4
34. Beevers G, Lip GYH, O'brien E; The Pathophysiology Of Hypertension ,
Bmj, 2001, Volume 322.
35. Gilbert RE, Jasik M, DeLuise M, O'Callaghan CJ, Cooper ME. Diabetes
and hypertension. In: Australian Diabetes Society position statement.
Medical Journal of Australian 1995; 163: 372-375.
36. Standley PR, Bakir MH, Sowers JR. Vascular insulin abnormalities,
hypertension, and accelerated atherosclerosis: Am J Kidney Dis. 1993
Jun;21(6 Suppl 3):39-46
37. Inoguchi T, Li P, Umeda F. High Glucose Level And Free Fatty Acid
Stimulate Reactive Oxygen Species Production Through Protein Kinase CDependent Activation Of Nad(P)H Oxidase In Cultured Vascular Cells.
Diabetes. 2000;49:1939-1945.
38. Ridwan M, Gotera W, Pengaruh Insulin Terhadap Fungsi Kardiovaskular; J
Peny Dalam, 2009, Volume 10, Nomor 2, p;151-152
55
39. Sowers Jr, Sowers Ps, Peuler Jd. Role Of Insulin Resistance And
Hyperinsulinemia In Development Of Hypertension And Atherosclerosis. J
Lab Clin Metab. 1994;123:647-652.
40. KimJ, MontagnaniM, KohKK,QuonMJ: Reciprocal Relationships Between
Insulin
Resistance
and
Endothelial
Dysfunction
Molecular
and
Pathophysiological Mechanisms ; Circulation. 2006;113:1888-1904.
41. Ramasamy R, Yan SF, Schmidt AM, Receptor for AGE (RAGE): signaling
mechanisms in the pathogenesis of diabetes and its complications, Annals
of the New York Academy of Sciences. 2011 Dec;43:88-102.
56